Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL

By Targeted Oncology · March 22, 2022

SCCA’s Ajay K. Gopal, MD, was featured in Targeted Oncology discussing the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy.

Read the article

B-cell lymphoma A type of cancer that forms in B cells (a type of immune system cell). B-cell lymphomas may be either indolent (slow-growing) or aggressive (fast-growing). Most B-cell lymphomas are non-Hodgkin lymphomas. A type of cancer that forms in B cells (a type of immune system cell). B-cell lymphomas may be either indolent (slow-growing) or aggressive (fast-growing). Most B-cell lymphomas are non-Hodgkin lymphomas. There are many different types of B-cell non-Hodgkin lymphomas. These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Prognosis and treatment depend on the type and stage of the cancer. Chimeric antigen receptor T-cell therapy A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then, in the laboratory, the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells. This special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. Chimeric antigen receptor T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called CAR T-cell therapy. Relapse The recurrence (return) of disease after an apparent recovery.

Back To: Newsroom